Online inquiry

IVTScrip™ mRNA-Anti-GUCY2C, MLN2045(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ11917MR)

This product GTTS-WQ11917MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 0 & 5-Methyl-CTP & Pseudo-UTP. It ecodes the monoclonal antibody that targets GUCY2C gene. The antibody can be applied in Cancers research.
Specifications
Product type mRNA
Modified bases 5-Methyl-CTP & Pseudo-UTP
5' Cap Cap 0
Species Homo sapiens
RefSeq NM_004963.4
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 2984
UniProt ID P25092
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-GUCY2C, MLN2045(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) (GTTS-WQ11917MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ6217MR IVTScrip™ mRNA-Anti-RABVgp4, CR4098(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA CR4098
GTTS-WQ492MR IVTScrip™ mRNA-Anti-IGHE, 47H4(Cap 0, Pseudo-UTP, 30 nt-poly(A)) mRNA 47H4
GTTS-WQ14137MR IVTScrip™ mRNA-Anti-PCSK9, aPCSK927(Cap 0, 2-Thio-UTP, 30 nt-poly(A)) mRNA aPCSK927
GTTS-WQ12372MR IVTScrip™ mRNA-Anti-SAA1, NEOD-001(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA NEOD-001
GTTS-WQ3449MR IVTScrip™ mRNA-Anti-S, AZD8895(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA AZD8895
GTTS-WQ13852MR IVTScrip™ mRNA-Anti-GCGR, REGN-1193(Cap 1, 5-Methyl-CTP, 120 nt-poly(A)) mRNA REGN-1193
GTTS-WQ10724MR IVTScrip™ mRNA-Anti-FCGRT, M-281(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA M-281
GTTS-WQ10845MR IVTScrip™ mRNA-Anti-FOLR1, M9346A(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA M9346A
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW